Rotavirus Vaccine
Return to Library
|
Free Rotavirus Vaccine Articles |
|
|
|
|
New research on life sciences from G. Davidson and co-authors summarized
2007 OCT 30 -- According to a study from Adelaide, Australia, "'From 1 July 2007 two new rotavirus vaccines licensed for use in Australia (RotaTeq CSL Biotherapies/Merck and Rotarix Glaxo Smith Kline) will be funded for the National Immunisation Program. The vaccines differ with respect to their composition and the timing and mode of administration." "Both have been evaluated in huge randomised trials and shown to be highly effective in preventing rotavirus gastroenteritis, including severe disease requiring hospital admission. Neither has been associated with an increased rate of intussusception; however, surveillance for adverse effects following, vaccination will be important," wrote G. Davidson and colleagues. The researchers concluded: "As rotavirus infection is ubiquitous in young children, funding of this vaccine will significantly decrease the enormous morbidity and costs associated with this disease in our community." Davidson and colleagues published the results of their research in the Journal of Paediatrics and Child Health (Preventing rotavirus gastroenteritis: Do you have the facts? Journal of Paediatrics and Child Health, 2007;43(7-8):564-567). For additional information, contact G. DavidsonWomen's & Children's HospitalGastrointestinal Unit, Discipline Pediatric, 72 King William Rd., Adelaide, SA 5006, Australia. The publisher of the Journal of Paediatrics and Child Health can be contacted at: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England. Keywords: Australia, Adelaide, Life Sciences, Pediatrics, Rotavirus Vaccine, Vaccination, Immunization, Biotechnology, Biological Therapy, Treatment, Gene Therapy, Virus, Viral, Gastroenteritis, Vaccines, Child Health. This article was prepared by Virus Weekly editors from staff and other reports. Copyright 2007, Virus Weekly via NewsRx.com.
|
